Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Nov;61(11):1628-1635.
doi: 10.2967/jnumed.119.239418. Epub 2020 Mar 20.

Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders

Affiliations

Confirmation of 123I-FP-CIT SPECT Quantification Methods in Dementia with Lewy Bodies and Other Neurodegenerative Disorders

Daniela D Maltais et al. J Nucl Med. 2020 Nov.

Abstract

Our rationale was to conduct a retrospective study comparing 3 123I-N-ω-fluoropropyl-2β-carbomethoxy-3β-(4-iodophenyl)nortropane (123I-FP-CIT) SPECT quantitative methods in patients with neurodegenerative syndromes as referenced to neuropathologic findings. Methods:123I-FP-CIT-SPECT and neuropathologic findings among patients with neurodegenerative syndromes from the Mayo Alzheimer Disease Research Center and Mayo Clinic Study of Aging were examined. Three 123I-FP-CIT SPECT quantitative assessment methods-MIMneuro, DaTQUANT, and manual region-of-interest creation on a workstation-were compared with neuropathologic findings describing the presence or absence of Lewy body disease (LBD). Striatum-to-background ratios (SBRs) generated by DaTQUANT were compared with the calculated SBRs of the manual method and MIMneuro. The left and right SBRs for caudate, putamen, and striatum were evaluated with the manual method. For DaTQUANT and MIMneuro, the left, right, total, and average SBRs and z scores for whole striatum, caudate, putamen, anterior putamen, and posterior putamen were calculated. Results: The cohort included 24 patients (20 [83%] male, mean age for all patients at death, 75.4 ± 10.0 y). The antemortem clinical diagnoses were Alzheimer disease dementia (n = 6), probable dementia with Lewy bodies (n = 12), mixed Alzheimer disease dementia and probable dementia with Lewy bodies (n = 1), Parkinson disease with mild cognitive impairment (n = 2), corticobasal syndrome (n = 1), idiopathic rapid-eye-movement sleep behavior disorder (n = 1), and behavioral-variant frontotemporal dementia (n = 1). Seventeen (71%) had LBD. All 3 123I-FP-CIT SPECT quantitative methods had an area under the receiver-operating-characteristics curve ranging from more than 0.93 to up to 1.000 (P < 0.001) and showed excellent discrimination between LBD and non-LBD patients in each region assessed (P < 0.001). There was no significant difference between the accuracy of the regions in discriminating the 2 groups, with good discrimination for both caudate and putamen. Conclusion: All 3 123I-FP-CIT SPECT quantitative methods showed excellent discrimination between LBD and non-LBD patients in each region assessed, using both SBRs and z scores.

Keywords: 123I-FP-CIT SPECT; 123I-ioflupane; Lewy body disease; dementia with Lewy bodies; neuropathology.

PubMed Disclaimer

Figures

None
Graphical abstract
FIGURE 1.
FIGURE 1.
Diagnostic accuracy using AUC of SBR and z scores for various ROIs as calculated by MIM, by DaTQUANT, and manually to differentiate between no LBD and LBD.
FIGURE 2.
FIGURE 2.
Correlations between programs using minimum caudate, minimum putamen, and minimum striatum SBRs (A) and z scores (B). ICC = intraclass correlation coefficient.
FIGURE 3.
FIGURE 3.
Box-and-whisker plots showing distribution of z scores and SBRs for minimum striatum, minimum caudate, and minimum putamen among LBD, mixed LBD and AD, and no-LBD neuropathologic diagnoses. *0.001 < P < 0.05. **P < 0.001.
FIGURE 4.
FIGURE 4.
Six patients who underwent 123I-FP-CIT SPECT and then neuropathologic examination. Clinical diagnoses before death and pathologic diagnosis are presented alongside each set of MRI coregistered images.

Similar articles

Cited by

References

    1. McKeith IG, Boeve BF, Dickson DW, et al. . Diagnosis and management of dementia with Lewy bodies: fourth consensus report of the DLB Consortium. Neurology. 2017;89:88–100. - PMC - PubMed
    1. Zupancic M, Mahajan A, Handa K. Dementia with Lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord. 2011;13:PCC.11r01190. - PMC - PubMed
    1. Williams MM, Xiong CJ, Morris JC, Galvin JE. Survival and mortality differences between dementia with Lewy bodies vs Alzheimer disease. Neurology. 2006;67:1935–1941. - PubMed
    1. Boström F, Jonsson L, Minthon L, Londos E. Patients with Lewy body dementia use more resources than those with Alzheimer’s disease. Int J Geriatr Psychiatry. 2007;22:713–719. - PubMed
    1. McKeith I, O’Brien JT, Walker Z, et al. . Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT-SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007;6:305–313. - PubMed

Publication types

Substances